David Bredt, Chief Scientific Officer at Rapport Therapeutics, Inc. (RAPP), sold 15,918 shares at $25.73 ($410K) on 2025-10-15, disclosed to the SEC on 2025-10-16.
Scheduled sale ($410k) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $25.73 | 7,418 | $191K | 46.5% |
| 2 | $25.73 | 7,418 | $191K | 46.5% |
| 3 | $26.16 | 1,082 | $28K | 6.9% |
| Total | $25.76 avg | 15,918 | $410K | 100% |
| Filing → |
| RAPP | SELL | 2026-01-05 | $395K | — | Filing → |
| RAPP | SELL | 2025-12-16 | $486K | — | Filing → |
| RAPP | SELL | 2025-11-18 | $428K | — | Filing → |